|
À̳ë¼Ä¡ |
ÇìµåÇåÅÍ Ãʺù
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇìµåÇåÅÍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.19 |
|
|
Ä¿¸®¾îÆ÷Ä¿½º |
Çã°¡ RA ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
¶óÀ̼¾½ºIn/Out |
5³â¡è |
ä¿ë½Ã |
03.14 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
Pharmacovigilance (MI) Specialist / Regulatory Affairs
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
03.14 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
[À¯¸í¿Ü±¹°è] ¾È°ú MR
¼¿ï °³²±¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
02.14 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
RA (1³â °è¾àÁ÷)
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
ä¿ë½Ã |
11.14 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
»óÀåÁß°ß±â¾÷ °³¹ßº»ºÎÀå ¸ðÁý
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.11 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
·ÎÄà ÀÓ»ó CRO»ç ÀÓ»ó BD °æ·ÂÀÚ Ã¤¿ë
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.11 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
»óÀå ´ë±â¾÷ ÀϺ»Çâ ÇØ¿Ü»ç¾÷ °æ·Â»ç¿ø ¸ðÁý
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.08 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
Áß°ß »óÀåÁ¦¾à»ç À繫°ü¸® °æ·Â»ç¿ø ¸ðÁý
¼¿ï °³²±¸ | Çз¹«°ü |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.08 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
»óÀåÁ¦¾à»ç °øÀγ빫»ç ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¼ö½Ãä¿ë |
2³â¡è |
ä¿ë½Ã |
10.08 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
³ª¿ìÆÊÄÁ¼³Æà 2018.10.8ÀÏÀÚ Ã¤¿ëÁ¤º¸ÀÔ´Ï´Ù
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.05 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
¹ÙÀÌ¿À ½Å¾à°³¹ß»ç MR(¼¿ï) °æ·Â ¸ðÁý
¼¿ï °³²±¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.05 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
Áß°ßÁ¦¾à»ç-°³¹ß±âȹ¾÷¹«(BD)
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.02 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
Áß°ßÁ¦¾à»ç ÀÓ»óÆÀÀå ä¿ë
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.02 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
Áß¼Ò Á¦¾à»ç °æ¿µ±âȹ½ÇÀå ¸ðÁý
¼¿ï °³²±¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.02 |
|